An ApoA1-modified tumor-derived exosome coupled with siRNA targeting neutral sphingomyelinase type 2 also effectively targeted tumor cells and enhanced the antitumor activity of CD8+ T cells by reducing the level of PD-L1 [137]. The gene discussed is CD8A; the disease is neoplasm.